{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:02:52Z","timestamp":1781326972399,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10351-4","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T02:50:36Z","timestamp":1748487036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib"],"prefix":"10.1007","volume":"42","author":[{"given":"Xi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"11","key":"10351_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"25","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG (2017) Understanding and targeting resistance mechanisms in NSCLC. Nat Reviews Cancer Oct 25(11):637\u2013658","journal-title":"Nat Reviews Cancer Oct"},{"issue":"6","key":"10351_CR2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"1","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh IJ et al (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol Jun 1(6):1409\u20131416","journal-title":"Ann Oncol Jun"},{"key":"10351_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","volume":"139","author":"K Nakagawa","year":"2020","unstructured":"Nakagawa K, Hida T, Nokihara H et al (2020) Final progression-free survival results from the J-ALEX study of alectinib versus Crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer Jan 139:195\u2013199","journal-title":"Lung Cancer Jan"},{"issue":"9","key":"10351_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"31","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus Crizotinib in untreated ALK-Positive Non-Small-Cell lung Cancer. N Engl J Med Aug 31(9):829\u2013838","journal-title":"N Engl J Med Aug"},{"issue":"5","key":"10351_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","volume":"7","author":"C Zhou","year":"2019","unstructured":"Zhou C, Kim SW, Reungwetwattana T et al (2019) Alectinib versus Crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med May 7(5):437\u2013446","journal-title":"Lancet Respir Med May"},{"issue":"1","key":"10351_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2019.12.042","volume":"1","author":"T Guo","year":"2020","unstructured":"Guo T, Ni J, Yang X et al (2020) Pattern of recurrence analysis in metastatic EGFR-Mutant NSCLC treated with osimertinib: implications for consolidative stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys May 1(1):62\u201371","journal-title":"Int J Radiat Oncol Biol Phys May"},{"key":"10351_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2017.03.010","volume":"108","author":"SH Patel","year":"2017","unstructured":"Patel SH, Rimner A, Foster A et al (2017) Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer Jun 108:109\u2013114","journal-title":"Lung Cancer Jun"},{"issue":"11","key":"10351_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","volume":"10","author":"H Al-Halabi","year":"2015","unstructured":"Al-Halabi H, Sayegh K, Digamurthy SR et al (2015) Pattern of failure analysis in metastatic EGFR-Mutant lung Cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol Nov 10(11):1601\u20131607","journal-title":"J Thorac Oncol Nov"},{"key":"10351_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lungcan.2019.02.020","volume":"130","author":"S Schmid","year":"2019","unstructured":"Schmid S, Klingbiel D, Aeppli S et al (2019) Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer Apr 130:149\u2013155","journal-title":"Lung Cancer Apr"},{"issue":"1","key":"10351_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13014-020-01651-y","volume":"27","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Ni J, Yu F et al (2020) The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease. Radiat Oncol Aug 27(1):207","journal-title":"Radiat Oncol Aug"},{"key":"10351_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2020.02.002","volume":"142","author":"OSH Chan","year":"2020","unstructured":"Chan OSH, Lam KC, Li JYC et al (2020) ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer Apr 142:41\u201346","journal-title":"Lung Cancer Apr"},{"issue":"7","key":"10351_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol Jul 17(7):976\u2013983","journal-title":"Lancet Oncol Jul"},{"issue":"1","key":"10351_CR13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1186\/s12885-021-08983-2","volume":"19","author":"T Miyawaki","year":"2021","unstructured":"Miyawaki T, Kenmotsu H, Kodama H et al (2021) Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC cancer Nov 19(1):1247","journal-title":"BMC cancer Nov"},{"issue":"12","key":"10351_CR14","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","volume":"7","author":"AJ Weickhardt","year":"2012","unstructured":"Weickhardt AJ, Scheier B, Burke JM et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol Dec 7(12):1807\u20131814","journal-title":"J Thorac Oncol Dec"},{"issue":"12","key":"10351_CR15","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr., Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol Dec 17(12):1672\u20131682","journal-title":"Lancet Oncol Dec"},{"issue":"1136","key":"10351_CR16","doi-asserted-by":"publisher","first-page":"20220035","DOI":"10.1259\/bjr.20220035","volume":"1","author":"D Xu","year":"2022","unstructured":"Xu D, Yu F, Guo T et al (2022) Clinical value of PET\/CT in identifying patients with oligometastatic\/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: implications from survival comparisons. Br J Radiol Aug 1(1136):20220035","journal-title":"Br J Radiol Aug"},{"issue":"1","key":"10351_CR17","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol Jan 14(1):e28\u201337","journal-title":"Lancet Oncol Jan"},{"issue":"10","key":"10351_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","volume":"1","author":"WJ Magnuson","year":"2017","unstructured":"Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of brain metastases in tyrosine kinase Inhibitor-Na\u00efve epidermal growth factor Receptor-Mutant Non-Small-Cell lung cancer: A retrospective Multi-Institutional analysis. J Clin Oncology: Official J Am Soc Clin Oncol Apr 1(10):1070\u20131077","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol Apr"},{"issue":"3","key":"10351_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ijrobp.2019.02.051","volume":"1","author":"E Miyawaki","year":"2019","unstructured":"Miyawaki E, Kenmotsu H, Mori K et al (2019) Optimal sequence of local and EGFR-TKI therapy for EGFR-Mutant Non-Small cell lung Cancer with brain metastases stratified by number of brain metastases. Int J Radiat Oncol Biol Phys Jul 1(3):604\u2013613","journal-title":"Int J Radiat Oncol Biol Phys Jul"},{"issue":"1","key":"10351_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12931-021-01741-9","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Nie W, Guo J et al (2021) Osimertinib alone as second-line treatment for brain metastases (BM) control May be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Respir Res May 11(1):145","journal-title":"Respir Res May"},{"issue":"3","key":"10351_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.05.125","volume":"1","author":"F Yu","year":"2021","unstructured":"Yu F, Ni J, Zeng W et al (2021) Clinical value of upfront cranial radiation therapy in Osimertinib-Treated epidermal growth factor Receptor-Mutant Non-Small cell lung Cancer with brain metastases. Int J Radiat Oncol Biol Phys Nov 1(3):804\u2013815","journal-title":"Int J Radiat Oncol Biol Phys Nov"},{"issue":"11","key":"10351_CR22","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","volume":"1","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel S, Peters S, Mok T et al (2018) Alectinib versus Crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol Nov 1(11):2214\u20132222","journal-title":"Ann Oncol Nov"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10351-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:13:01Z","timestamp":1757175181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["10351"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10351-4","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the institutional ethical committees of Fudan University Shanghai Cancer Center (NO. 1612167-18). The study was conducted according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}